KAKalyani Asgaonkar

Kalyani Asgaonkar

*This is an algorithmically generated author record based on publicly available information.

Kalyani Asgaonkar has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Harnessing Annona muricata phytochemicals for multi-target cancer therapy: An integrated network pharmacology and in-silico study

    by Shital M. Patil, Abhijit Das, Kalyani Asgaonkar, Kalirajan Rajagopal, Amruta Avalaskar, Gautam Gundecha, Krishna Shevate, Pranjal Gavali, Prerana Bhosale

  • Integrated LC-MS and Computer-aided Drug Design Evaluation of Sida cordifolia Herbal Microemulsion Targeting Inflammatory Enzymes through Molecular Docking, MM-GBSA, DFT, and ADMET Profiling

    by Kalyani Asgaonkar, Amruta Avalaskar, Kalirajan Rajagopal, Krishna Shevate, Shital Patil, Trupti Chitre, Gajanan Rathod, Pranaya Nawale, Varun Hambir, Prachi Divate

    Introduction: Sida cordifolia(SC) L. is traditionally used to treat inflammatory disorders; however, its molecular composition and mechanisms of action remain poorly understood. This study aimed to investigate its bioactive constituents and evaluate their anti-inflammatory potential using integrated computational and experimental approaches. materials and methods: Phytochemical profiling of SC extract was performed using LC–MS. Identified compounds were assessed for pharmacokinetic and toxicity properties via in silico ADME–Tox prediction. Molecular docking was conducted against key inflammatory enzymes, including secretory phospholipase A₂ (sPLA₂), 5-lipoxygenase (5-LOX), and cyclooxygenase-2 (COX-2). An oil-in-water microemulsion was formulated and characterized for physicochemical properties. Anti-inflammatory activity was evaluated using egg albumin denaturation, heat-induced hemolysis, and in vivo rat paw edema assays. results: Thirteen bioactive phytochemicals were identified and structurally characterized. ADME–Tox predictions indicated favorable pharmacokinetic profiles with low toxicity. The microemulsion showed good stability and suitable physicochemical properties. Docking results revealed strong binding affinities of quinazoline alkaloids and prenylated flavonoids with sPLA₂, 5-LOX, and COX-2, suggesting multi-target inhibition. Experimental assays demonstrated significant anti-inflammatory activity. discussion: The findings indicate that Sida cordifolia contains bioactive phytochemicals capable of targeting key inflammatory enzymes (sPLA₂, 5-LOX, and COX-2). Favorable docking interactions and ADME–Tox profiles, along with the stable microemulsion formulation, support enhanced delivery and activity. The significant effects observed in in vitro and in vivo models suggest a multi-target anti-inflammatory mechanism, supporting the plant’s traditional therapeutic use. conclusion: These findings highlight SC as a promising source of multi-target anti-inflammatory agents. The combined computational, in vitro, and in vivo approaches, along with microemulsion-based delivery, support its therapeutic potential.

  • Unveiling the Research Landscape of Triazole-based Aromatase Inhibitors in Breast Cancer: Bibliometric Insights

    by Trupti S. Chitre, Kalyani D. Asgaonkar, Sonali S. Shelake, Rutuja C. Joshi, Anchal D. Yadav, Pranjali A. Nandanwar, Sakshi R. Gaikwad

    Introduction: Breast cancer remains a leading cause of death among women, with one life lost approximately every 13 minutes. Postmenopausal women are particularly susceptible to Estrogen Receptor-positive (ER+) breast cancer. Aromatase inhibitors, including letrozole, exemestane, and anastrozole, suppress estrogen synthesis in peripheral tissues, thereby improving survival rates and reducing the risk of recurrence. Methods: Scopus database was searched for literature on triazole-based aromatase inhibitors in breast cancer. Data on countries, institutions, authors, citations, and key terms were analyzed and visualized using VOSviewer and RAWGraphs. Results: A total of 804 relevant publications were identified, showing a marked increase in research activity in recent years. The United States (345 publications; 28,920 citations) and the United Kingdom (196 publications; 16,021 citations) emerged as leading contributors. The Mayo Clinic, Rochester, United States, recorded the highest institutional citation impact (3,540 citations). Discussion: The upward trend in publications reflects growing global interest in triazole-based aromatase inhibitors, with research output concentrated in a few leading centers in the US and UK. Expanding international collaboration could broaden the clinical evidence base and improve therapeutic accessibility. Advances in molecular design and pharmacokinetic optimization are evident; however, challenges remain in translating laboratory findings to clinical settings, particularly in overcoming drug resistance and addressing variability in patient response. Conclusion: Since 1989, substantial progress has been made in the development of triazolebased aromatase inhibitors for breast cancer. Continued innovation and global collaboration are essential to refine treatment strategies and enhance patient outcomes.

  • Design, synthesis and in-silico studies of new triazole–thiazole derivatives as potential antimicrobial agents

    by Vilas G. Sisode, Manish Bhoye, Kalyani D. Asgaonkar, Shital M. Patil, Nitin S. Pagar, Pravin C. Mhaske


  • Rational Design of Indole Analogs against Nosocomial Infections Using Integrated 3D QSAR, ADMET, and Docking Approaches

    by Kalyani Asgaonkar, Dipti Ghate, Akshata Naik, Parth Shah, Shubham Kachare, Shital Patil, Trupti Chitre

    Introduction: In India, more than 1.4 million people annually succumb to nosocomial infections, primarily in hospitals, largely due to the prevalence of multidrug-resistant bacteria, which pose significant treatment challenges. The aim of the present study was to design new chemical entities (NCEs) against Staphylococcus aureus nosocomial infections using in silico approaches, including 3D-QSAR, pharmacophore modeling, virtual screening, ADMET prediction, and molecular docking. Methods: A dataset of 24 Indole derivatives was obtained from the literature, and 3D-QSAR was performed to investigate the relationship between the molecular structures of the target compounds and their antibacterial activity. Subsequently, NCEs were designed through virtual screening and molecular modeling studies, including ADMET and docking in the crystal structure of DNA gyrase, to prove the hypothesis. Results: The 3D-QSAR model successfully explained the structural requirements for activity, with DHRRR_1 emerging as the most predictive hypothesis. Virtual screening led to the generation of a focused NCE library, which was refined based on ADMET properties and druglikeness criteria. Molecular docking revealed that the majority of NCEs displayed a strong binding affinity and favorable interactions within the DNA gyrase active site, supporting their potential as antibacterial candidates. Discussion: The integration of 3D-QSAR, pharmacophore modeling, and molecular docking provided valuable insights into the design of novel indole-based scaffolds with activity against S. aureus. In silico ADMET screening ensured identification of compounds with acceptable pharmacokinetic profiles. These findings highlight the promise of structure-guided approaches in overcoming bacterial resistance mechanisms. Conclusion: These results provided meaningful design guidance for the development of novel antibacterial compounds in the research for nosocomial infections.

  • A Quantitative Bibliometric and Patentometric Study on the Role of HER2 in Breast Cancer: A Review

    by Kalyani Asgaonkar, Shital Patil, Trupti Chitre, Tina Saldanha, Shubham Kachare, Vaishnavi Rathod

    Introduction: Breast cancer is not only the most prevalent form of cancer, but also the second leading cause of cancer-related mortality in women. In recent years, there has been a growing interest in learning more about the processes behind the development and treatment of breast cancer. This study aimed to undertake a bibliometric analysis of research on breast cancer and human epidermal growth factor receptor 2, highlighting principal research trends, dynamics, and scientific outputs in the field. Method: Research and review publications, as well as patents on breast cancer and HER2, were retrieved from the Scopus database and WIPO patent scope. The bibliometric tool VOSviewer was employed for data analysis and visualization. Results: The analysis revealed the prominent role of the countries, authors, journals, and organizations in exploring this area in research papers, and data on patents showed an increase in patenting activity. Discussion: Our study revealed a significant exponential growth in publications on this topic over the last decade, with the high-impact Journal of Clinical Oncology exhibiting the maximum co-citations. Researcher Rugo, H.S., had the highest number of publications and citations. The A61K code was the highest, related to preparations for medical purposes. Jens Fritsche was found to work on the top patents. Genentech Inc. filed the highest number of applications, and the USA showed the highest number of research papers and patenting activities. Conclusion: The information provided in this article may help researchers to better understand hotspots and developing patterns in this research area. This study has advocated for the exploration of innovative HER2-targeting therapies that could revolutionize breast cancer treatment.

  • Design and development of pyrazole–thiazole hybrid derivatives as anti-inflammatory and anti-oxidant agents

    by Shital M. Patil, Omkar Kamble, Kalyani Asgaonkar, Shashikant Bhandari, Trupti Chitre, Vaishnavi Rathod, Prerana Bhosale, Pranjal Gavali, Abhijit Das


  • Open Access

    ADME, Synthesis and Antimycobacterial Activity of 1,2,4-Triazol-3-thiol Linked Phenylacetamide Derivatives

    by Trupti Chitre, Shivani Jadhav, Kalyani Asgaonkar, Kunal Pradhan, Kalash Shelke, Shubhangi Thorat, Aniket Bhatambrekar

    Background:: Tuberculosis (TB) is caused by Mycobacterium tuberculosis and is one of the most contagious and fatal human pathogens which necessitates the development of modified existing drugs or derivatives with action against novel targets. Aims and Objectives:: In the present work, we have explored a few, 2-(5-(substituted)-4H-1,2,4-triazole-2-ylthio)-N-(substituted) phenyl acetamide (5A-5E) derivatives as anti-TB. Materials and Methods:: On the basis of SAR were synthesized and screened against Mycobacterium tuberculosis H37Rv using MABA assay. Their ADME properties were also checked. Results:: ADME analysis showed results comparable with standard drug (rifampicin). Derivative 5D turned out to be the most active amongst all the derivatives with MIC of 0.8μg/ml, comparable to standard drugs like rifampicin(0.8μg/ml) and streptomycin(0.8μg/ml). Conclusion:: All five compounds have shown excellent inhibitory activity (1.6μg/ml) against the Mycobacterium tuberculosis H37Rv strain. Compound 5D shows a promising activity (0.8μg/ml) as compared to standard drugs and also it has shown the highest docking score. Literature search has revealed the presence of 1,2,4-triazole derivatives linked to aromatic link and possessing amide linkage and the presence of Sulphur atom in the most active derivatives, which supports our designed compounds. Based on these findings, further derivatives would be synthesized and explored for their role in tuberculosis.

  • Development of 7H-pyrrolo[2,3-d]pyrimidin-4-amine Derivatives Using QSARINS Tool as BTK Inhibitors for the Treatment of Rheumatoid Arthritis

    by Shital M. Patil, Kalyani. D. Asgaonkar, Pradnya Magdum, Vaishnavi Chinde, Aishwarya Edake, Akshata Naik

    Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the joints, leading to pain, swelling, and joint deformity. Among the potential targets for RA treatment is Bruton's tyrosine kinase (BTK), which plays a crucial role in B-cell signaling and contributes to the pathogenesis of RA.In present work this software was explored for pharmacophore optimization of the pyrrolo- pyrimidine nucleus for antirheumatoid activity.This research provided valuable insights into the structural features essential for BTK inhibition and paves the way for the design and development of novel anti-rheumatic agents targeting BTK in RA.